Coxiella burnetii (Phase II) (Antigen) 1123

$75.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Cost-effective due to standardized reagents
Lyophilized antigens, control antigens as well as positive and negative control sera simplify storage
Suitable screening test to identify acute infections
Compensation of seroprevalences allow high specificity

SKU: 1123 Category: Infectious disease proteins Tags: antigen, Coxiella burnetii, protein

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Coxiella burnetii phase II immunoglobulins
species reactivity	Coxiella burnetii (Q fever)
applications	CFT (Complement fixation test)
assay type	qualitative
available size	100 µL

Coxiella burnetii (Phase II) (Antigen) 1123

kit
Research area Infectious Disease
Storage Store at -65°C. Avoid freeze/thaw cycles. Sonicate before use.
Associated products Coxiella burnetii Phase 2 IgG Control Serum (BC1312G) Coxiella burnetii Phase 2 IgM Control Serum (BC1312M) Coxiella burnetii IgA Phase I ELISA Kit (ESR1311A) Coxiella burnetii IgG Phase I ELISA Kit (ESR1311G) Coxiella burnetii IgG Phase II ELISA Kit (ESR1312G) Coxiella burnetii IgM Phase II ELISA Kit (ESR1312M)

target relevance
Organism Coxiella burnetii
Protein names Coxiella burnetii
Structure and strains Coxiella burnetii is an obligate intracellular bacterial pathogen, and is the causative agent of Q fever. The genus Coxiella is morphologically similar to Rickettsia, but with a variety of genetic and physiological differences. C. burnetii is a small Gram-negative, coccobacillary bacterium that is highly resistant to environmental stresses such as high temperature, osmotic pressure, and ultraviolet light. These characteristics are attributed to a small cell variant form of the organism that is part of a biphasic developmental cycle, including a more metabolically and replicatively active large cell variant form. It can survive standard disinfectants, and is resistant to many other environmental changes like those presented in the phagolysosome.
Detection and diagnosis The diagnosis of Q fever is performed by the demonstration of specific antibodies directed against Coxiella burnetii. Due to variations in the lipopolysaccharide (LPS) structure on the surface of the pathogen, as the disease enters the chronic state, a serological differentiation of acute from chronic infections is possible. Due to the high sensitivity and specificity, the use of ELISA immunoassays is recommended by the World Health Organization (WHO). Following the regular course of an acute primary infection, specific IgM and IgG antibodies directed against the immunogenic phase 2 antigens can be demonstrated. IgG antibodies directed against phase 2 antigens often persist over several years. In the lead-up to a chronic infection, IgG and IgA antibodies directed against the phase 1 antigens appear, which are of diagnostic value particularly for the diagnosis of Q fever endocarditis

Data

FAQ & Publications

Frequently Asked Questions

What is the recommended storage condition for the Coxiella burnetii (Phase II) Antigen 1123 to maintain its stability?

The Coxiella burnetii (Phase II) Antigen 1123 should be stored at -65°C and freeze/thaw cycles should be avoided to maintain its stability. Additionally, the antigen should be sonicated before use.

For which applications and species reactivity is the Coxiella burnetii (Phase II) Antigen 1123 primarily intended?

This antigen is intended for qualitative applications such as the Complement Fixation Test (CFT) and is reactive to Coxiella burnetii phase II immunoglobulins, specifically targeting Coxiella burnetii, the causative agent of Q fever.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.